SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors", authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer in the April issue of Molecular Therapy. The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including the selection of appropriate clinical trial endpoints, selection of patients who are likely responders to therapeutic stimulation of collateral development, and potential genetic and molecular markers in patient screening. The abstract of the publication is now available at www.nature.com/mt/journal/v21/n4/abs/mt201313a.html (membership required for full viewing). The Company will mail the full article to interested parties upon request by contacting Cardium at 858-436-1000. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) "In this recent publication, I have summarized the lessons learned during the past 15 years of pre-clinical and clinical research and development efforts in the field of therapeutic angiogenesis using growth factor proteins and genes. I also described in some detail the specific insights that our team, first at Schering AG (now part of Bayer Healthcare) and now at Cardium, has gained in the course of the development of Generx, one of the most advanced therapeutic angiogenesis product candidates. These lessons have been invaluable and they have been incorporated into the trial design of the Generx ASPIRE pivotal Phase 3 clinical study now underway at several leading cardiovascular centers in the Russian Federation," stated Dr. Rubanyi. Before joining Cardium in March 2006, Dr. Rubanyi was vice president of gene therapy at Berlex Biosciences (a subsidiary of Berlex Laboratories, the U.S. pharmaceutical affiliate of the Schering AG Group, Germany). He played a leading role in the development of angiogenic gene therapy at Schering/Berlex in association with a strategic partnership with Collateral Therapeutics. In 2002, Schering AG acquired Collateral Therapeutics, and in 2005, Cardium Therapeutics acquired the technology and product candidates, including Generx, from Schering AG. About Generx Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease state and may benefit from a biological therapy that enhances cardiac perfusion through the facilitation of collateral vessel formation. Currently, patient inclusion in the ASPIRE study requires evidence of stress induced reversible myocardial ischemia as measured by SPECT imaging. The goal of the Company's Generx product candidate is to improve blood flow to the heart muscle by promoting and enhancing cardiac perfusion through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). Various catheter-based imaging diagnostics including fractional flow reserve and washout collaterometry could enhance the clinical adoption of this non-surgical therapeutic angiogenesis approach following initial registration.